CPRX — CATALYST PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1369568 ·
Last close
$31.47
Market Cap
$3.85B
52W High
$32.56
52W Low
$24.69
ADV30
1,873,233
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 149,390,000 | 134,915,000 | 73,232,000 | 63,734,000 | 1,147,610,000 | 755,859,000 | 134,913,000 |
| Dec 2025 | 152,613,000 | 126,539,000 | 61,846,000 | 52,698,000 | 1,103,979,000 | 709,171,000 | 149,711,000 |
| Sep 2025 | 148,392,000 | 125,738,000 | 66,267,000 | 52,783,000 | 1,051,602,000 | 689,892,000 | 131,357,000 |
| Jun 2025 | 146,563,000 | 125,949,000 | 66,298,000 | 52,108,000 | 971,915,000 | 652,800,000 | 115,888,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$208,214,000
Investing CF
$-85,000
Financing CF
$-32,926,000
CapEx
$-406,000
Dividends Paid
—
Buybacks
$-39,874,000
EPS Diluted TTM
$1.74
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$523,349,000
Inventory
$34,930,000
Receivables
$131,306,000
ST Investments
—
EBIT TTM
$73,232,000
Pretax Income TTM
$296,458,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$596,958,016
EBITDA
$305,828,992
Free Cash Flow
$171,809,872
Enterprise Value
$3,098,151,936
Total Cash
$755,859,008
Total Debt
$2,681,000
Shares Out
122,417,458
Trailing EPS
$1.73
Book Value
$8.29
ROE
24.5%
ROA
16.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 588,989,000 | 257,778,000 | 214,326,000 | 1,103,979,000 | 149,711,000 | — | 208,670,000 |
| Dec 2024 | 491,734,000 | 195,124,000 | 163,889,000 | 851,411,000 | 123,779,000 | — | 239,808,000 |
| Dec 2023 | 398,204,000 | 86,812,000 | 71,410,000 | 470,114,000 | 82,233,000 | — | 143,600,000 |
| Dec 2022 | 214,203,000 | 101,838,000 | 83,079,000 | 375,630,000 | 75,209,000 | — | 116,047,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.87B | $23.42 | — |
| GPCR | Structure Therapeutics Inc. | $3.79B | $53.36 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.77B | $11.14 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.65B | $51.09 | — |
| RCUS | Arcus Biosciences, Inc. | $3.64B | $28.92 | — |
News headlines (Yahoo Finance, 1h cache)
Why Solaris Energy Infrastructure (SEI) Stock Is Up Today
2026-07-10 22:31 · Yahoo
Sector Update: Energy Stocks Advance Pre-Bell Friday
2026-07-10 13:23 · Yahoo
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
2026-07-10 10:03 · Yahoo
SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying
2026-07-10 00:02 · Yahoo
Solaris Energy Infrastructure Set to Join S&P SmallCap 600
2026-07-09 21:47 · Yahoo
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
2026-07-02 13:34 · Yahoo
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
2026-07-01 05:00 · Yahoo
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
2026-06-30 12:03 · Yahoo
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
2026-06-10 15:30 · Yahoo
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
2026-05-20 21:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.